As the US Food and Drug Administration (FDA), industry and other stakeholders continue to meet and discuss what provisions the next iteration of the Generic Drug User Fee Act (GDUFA) should contain in ...
The US Food and Drug Administration (FDA) on Tuesday finalized guidance to help sponsors understand how the review goals established as part of the Generic Drug User Fee Amendments Reauthorization of ...
The Generic Drug User Fee Amendments, designed to facilitate the delivery of safe and effective generic drugs to the public and improve the predictability of the ANDA assessment process, has undergone ...
Q&A on GDUFA implementation with Aloka Srinivasan, PhD, a principal consultant with Parexel and former team leader in FDA's Office of Generic Drugs. On July 9, 2012, the Generic Drug User Fee Act ...
FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is "substantially complete” and received for review. Assigned GDUFA goal date is July 29, 2026. NRx has applied to FDA for use of ...
FDA clarifies GDUFA requirements in regards to abbreviated new drug applications and prior approval supplements. FDA has released two guidance documents relating to the submission of abbreviated new ...
HYDERABAD: Citing high workload, the US Food and Drug Administration (USFDA) has increased fee for processing Abbreviated New Drug Application (ANDA) by over USD 1 lakh to USD 1.71 lakh for the fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results